Population-based registry analysis of cervical cancer trends in Tashkent, Uzbekistan 2014-2024.
8 affiliations
- 1Department of Microbiology and Antimicrobial Resistance, National Biopharmaceutical Research Institute, Tashkent, Uzbekistan.
- 2Department of Life Sciences, Pharmaceutical Technical University, Tashkent, Uzbekistan.
- 3Department of Preventive Service, Kyoto University, Kyoto, Japan.
- 4Department of Oncology and Hematology, National Children's Medical Center, Tashkent, Uzbekistan.
- 5Department of Oncology, Tashkent State Medical University, Tashkent, Uzbekistan.
- 6Department of Treatment Management, Ministry of Health of Uzbekistan, Tashkent, Uzbekistan.
- 7Department Strategic Planning, Ministry of Health of Uzbekistan, Tashkent, Uzbekistan.
- 8Tashkent City Branch of Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Oncologic Gynecology, Tashkent, Uzbekistan.
Abstract
Background
Cervical cancer remains a leading cause of morbidity and mortality among women in Uzbekistan, exceeding WHO elimination targets. Despite a school-based HPV vaccination program launched in 2019, screening coverage remains low, leading to delayed diagnoses; we examined cervical cancer trends in Tashkent (2014-2024) to evaluate the impact of the Korea Foundation for International Healthcare (KOFIH) screening project and UNFPA/UNDP HPV testing initiatives.Methods
We analyzed Tashkent City Oncoregister data for women diagnosed with invasive cervical cancer or carcinoma in situ (CIS) between 2014 and 2024 (n = 2140) after data cleaning. We calculated age-standardized incidence and mortality rates, assessed survival using Kaplan-Meier methods, and identified mortality predictors using Cox regression models.Results
The age-standardized incidence of invasive cervical cancer was 14.9 per 100 000. After KOFIH and UNFPA/UNDP implementation, CIS diagnoses increased 3.4-fold (0.2-4.7 per 100 000), while the proportion of advanced-stage (III-IV) disease declined by 43%. Five-year survival showed clear stage dependence, ranging from 91.5% for CIS to 27.8% for stage IV. Age and stage were independent predictors of mortality. Crude mortality declined from 10.2 to 1.1 per 100 000 from 2014 to 2024, and case fatality decreased from 48.6% (2014-2019) to 27.2% (2020-2024).Conclusion
Organized screening through KOFIH and UNFPA initiatives can improve early detection and reduce mortality. However, 76.6% of staged invasive cases remain advanced (II-IV), and more than 80% of women have never been screened, underscoring the need to expand screening, sustain HPV vaccination, and strengthen prevention programs in Central Asia.
Related
- Clinical features of COVID-19 patients hospitalized at the Tashkent State Medical University and risk factors for intensive care unit admission: a cross-sectional study from Uzbekistan, Central Asia
- Clinical yield and operational cost-threshold analysis of HPV self-sampling send-outs for long-term non-attenders in cervical cancer screening: a population-based, real-world, registry study in Sweden
- Regional disparities in lung cancer surgery and survival in South Korea: a nationwide population-based retrospective cohort study using linked cancer registry and national health insurance data
- SARS-CoV-2 seroprevalence and extent of infection under-ascertainment in seven regions of Uzbekistan: a population-based serosurvey, May–July 2022
- Surgical quality and long-term outcomes in advanced ovarian cancer: a population based registry study from Hamburg, Germany 2014-2024.
BibTeX
@article{mirzaev2026populationbased,
title = {{Population-based registry analysis of cervical cancer trends in Tashkent, Uzbekistan 2014-2024.}},
author = {Ulugbek Khudayberdievich Mirzaev and Jasur Ravshanovich Juraev and Iroda Pulatovna Sharipova and Sarvar Temurovich Islomov and Nodira Isroilovna Tursunova and Sitora Rakhmatova and Fatima Shokir Qizi Shodieva and Mirzarakhim Mirzakhakimovich Baynazarov and Khasanjon Kobiljon Ugli Odilov and Dilbar Yuldashevna Yuldasheva and Golib Abdulloyevich Khakimov},
journal = {JNCI cancer spectrum},
year = {2026},
month = sep,
doi = {10.1093/jncics/pkag107},
url = {https://europepmc.org/article/MED/42853092},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Population-based registry analysis of cervical cancer trends in Tashkent, Uzbekistan 2014-2024.
AU - Ulugbek Khudayberdievich Mirzaev
AU - Jasur Ravshanovich Juraev
AU - Iroda Pulatovna Sharipova
AU - Sarvar Temurovich Islomov
AU - Nodira Isroilovna Tursunova
AU - Sitora Rakhmatova
AU - Fatima Shokir Qizi Shodieva
AU - Mirzarakhim Mirzakhakimovich Baynazarov
AU - Khasanjon Kobiljon Ugli Odilov
AU - Dilbar Yuldashevna Yuldasheva
AU - Golib Abdulloyevich Khakimov
PY - 2026
DA - 2026/09/01
JO - JNCI cancer spectrum
DO - 10.1093/jncics/pkag107
UR - https://europepmc.org/article/MED/42853092
AB - Background Cervical cancer remains a leading cause of morbidity and mortality among women in Uzbekistan, exceeding WHO elimination targets. Despite a school-based HPV vaccination program launched in 2019, screening coverage remains low, leading to delayed diagnoses; we examined cervical cancer trends in Tashkent (2014-2024) to evaluate the impact of the Korea Foundation for International Healthcare (KOFIH) screening project and UNFPA/UNDP HPV testing initiatives.Methods We analyzed Tashkent City Oncoregister data for women diagnosed with invasive cervical cancer or carcinoma in situ (CIS) between 2014 and 2024 (n = 2140) after data cleaning. We calculated age-standardized incidence and mortality rates, assessed survival using Kaplan-Meier methods, and identified mortality predictors using Cox regression models.Results The age-standardized incidence of invasive cervical cancer was 14.9 per 100 000. After KOFIH and UNFPA/UNDP implementation, CIS diagnoses increased 3.4-fold (0.2-4.7 per 100 000), while the proportion of advanced-stage (III-IV) disease declined by 43%. Five-year survival showed clear stage dependence, ranging from 91.5% for CIS to 27.8% for stage IV. Age and stage were independent predictors of mortality. Crude mortality declined from 10.2 to 1.1 per 100 000 from 2014 to 2024, and case fatality decreased from 48.6% (2014-2019) to 27.2% (2020-2024).Conclusion Organized screening through KOFIH and UNFPA initiatives can improve early detection and reduce mortality. However, 76.6% of staged invasive cases remain advanced (II-IV), and more than 80% of women have never been screened, underscoring the need to expand screening, sustain HPV vaccination, and strengthen prevention programs in Central Asia.
SN - 2515-5091
ER -